Stock Ratings / Health Care / BSEM / options

CVM (36) EVAX (48) GNTA (50) MGX (24) ⌘ Pro Terminal →

BioStem Technologies Inc. (BSEM) Options Positioning, Max Pain & Unusual Sweeps

Q: What is BSEM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BSEM.

$1.12 -13.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.09

BioStem Technologies Inc. (BSEM) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $24.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BSEM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BSEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, BioStem Technologies Inc. (NASDAQ: BSEM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.12 (-13.18% 1D, market cap $24.1M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BSEM ranks #690 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BSEM compare to CVM and EVAX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BSEM carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 93.6%, and ROIC of -5.7%. By comparison, CVM (Cel-Sci Corporation) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $26.4M) and EVAX (Evaxion A/S) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $27.8M). Among the 5-stock peer group, BSEM leads on earnings multiple (N/A) while BSEM leads on capital efficiency (-5.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BSEM?

▼

Per BSEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658678), BioStem Technologies Inc. generated $47.5M in revenue (-31.8% YoY), -$6.6M in net income, and $6.6M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.09 (-2.56%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 13.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BSEM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY BSEM SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+11/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($6.6M FCF) & 93.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 2.44 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.44-36.9% Next Q

Q2 (-2Q)

Grade D$1.54+0% Next Q

Q3 (-1Q)

Grade E$1.54-27.3% Next Q

Current

Grade D-$1.12-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BSEM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BSEM currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.04) and Max Pain ($1.18) forces dealer call-delta covering toward $8.82.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BSEM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BSEM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BSEM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BSEM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BSEM)

✓Walkthrough of BSEM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BSEM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -74.55%🛡️ HOLDING TREND SUPPORT

2026-11-02O $1.51H $1.51L $1.12C $1.12VOL 263.7K

RES: $6.00SUP: $0.94SMA50: $3.04SMA200: $4.18

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BSEM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BSEM Butterfly Map → + Track BSEM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -31.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BSEM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BSEM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BSEM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BSEM)

Health Care Rank #690 of 1016 ⚔️ CVM vs BSEM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BSEM vs. CVM, EVAX, GNTA, MGX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioStem Technologies Inc. (BSEM) ranks #690 by composite RQD confidence (35/100, grade D-) and #821 by equity capitalization ($24.1M). Within this direct 5-issuer industry benchmark cohort, BSEM leads on earnings valuation at N/A trailing P/E, while BSEM leads on capital efficiency and profitability with -5.7% ROIC and 93.6% gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with BSEM at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BSEM ACTIVE BioStem Technologies Inc.	D-	35/100	—	93.6%	-5.7%	-13.18%	$24.1M	Benchmark Subject
CVM Cel-Sci Corporation	D-	36/100	—	—	-35.0%	-8.00%	$26.4M	/cvm-vs-bsem →
EVAX Evaxion A/S	D	48/100	—	—	—	-4.87%	$27.8M	/evax-vs-bsem →
GNTA Genenta Science S.p.A.	D	50/100	—	—	—	-0.27%	$29.9M	/gnta-vs-bsem →
MGX Metagenomi Therapeutics Inc.	E	24/100	—	—	-35.0%	-6.01%	$31.4M	/mgx-vs-bsem →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001658678

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioStem Technologies Inc. (BSEM) reported GAAP revenue of $47.5M (-31.8% vs. FY2024 revenue of $69.7M ) , GAAP net income of -$6.6M, operating cash flow of $9.9M, and free cash flow of $6.6M (-72.6% YoY). On the balance sheet, BSEM closed FY2025 with $50.0M in total assets against $0 in total debt (Altman Z-Score: 2.44, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$47.5M	-$6.6M	$9.9M	$6.6M	$50.0M	—
FY2024 (FY)	2024-12-31	$69.7M	$31.0M	$24.5M	$24.0M	$58.3M	—

3. BSEM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BSEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BSEM compare to CVM and EVAX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BSEM?

Where is BSEM trading relative to its 50-day, 200-day, and 52-week technical levels?

BSEM last traded at $1.12 (-13.18% on volume of 145,605 shares), positioning the stock -63.16% below its 50-day simple moving average ($3.04) and -73.21% below its 200-day simple moving average ($4.18). Across its 52-week range of $1.11 to $8.40, BSEM sits at the 0.1% percentile with a 14-day RSI of 28.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.26).

BSEM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BSEM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BSEM.

Direct Sub-Reports: BSEM RQD Cockpit BSEM 12M Forecast BSEM Earnings & Move BSEM Dividends & DRIP BSEM Insiders & 13F BSEM Whale Options BSEM Profit Sankey BSEM News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BSEM — BioStem Technologies Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BSEM scores 35 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 11/20 (ROIC of -5.7% and FCF yield of 0%); Whale 13F Flow at 3/20 (institutional accumulation and options positioning); Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (beta of 1.0 and sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.44, Piotroski F 5/9, Debt/Equity 0.5). For a prospective investor, the weakest pillar is institutional flow at 3/20, indicating little visible institutional support in the source data, while the fundamental cash engine's negative ROIC and zero FCF yield limit near-term upside drivers. The forensic balance sheet is the relative strength within a weak profile, with an Altman Z of 2.44 and a Debt/Equity of 0.5. Valuation tradeoffs cannot be fully assessed because P/E and EV/EBITDA are not available in source data, and the recent price decline of -14.57% sits against a 52-week range of $1.11 - $8.4, meaning the shares trade near the low end of their annual band.

Business

BioStem Technologies Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. Per the SEC financials, the company reported revenue of $47.5M for FY 2025, down from $69.7M in FY 2024. The source data does not specify its product lines, customer base, or detailed revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$47.5M	$-0.7M	$-6.6M	N/A	$6.6M	$29.5M	N/A
FY 2024 (filed 2024-12-31)	$69.7M	$31.1M	$31.0M	N/A	$24.0M	$22.8M	N/A

Per the SEC financials, the company moved from positive operating and net income in FY 2024 to losses in FY 2025, with net margin of -13.9% and operating margin of -1.5% in the market data section, against a gross margin of 93.6%. ROIC is -5.7%. Per the Roarable RQD rating, the Altman Z-Score is 2.44 and the Piotroski F-Score is 5/9. The Debt/Equity ratio is 0.5, and reported cash rose to $29.5M in FY 2025, though debt figures are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news wire, several items concern insider option exercises: the COO was reported as exercising options to acquire 250,000 shares at $2 per share, and the CEO and COO together were reported as investing $1 million in cash through option exercises. A separate report states the CEO exercised options for 250,000 shares at $2 per share. Third-quarter results are scheduled for release on Nov. 12, with management discussing them at 4:30 p.m. ET. An SEC filing dated Oct 13, 2026 is also referenced. Each news item is rated YELLOW by the source feed. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no additional sector signals are available.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peer companies cannot be assessed from these sources.

Open Questions

What are the company's current debt obligations, given that debt is listed as N/A in both reported periods?
What drove the swing from $31.0M net income in FY 2024 to $-6.6M in FY 2025, and what is the revenue mix behind the $69.7M to $47.5M decline?
What is the reported EPS, since the source lists EPS as N/A for both periods?
Will the Nov. 12 third-quarter results confirm or change the FY 2025 loss trajectory?
What is the purpose and disclosure context of the insider option exercises relative to the current share price?

BSEM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioStem Technologies Inc. (BSEM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BSEM Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 11h ago

BioStem Technologies, Inc. Estimates – NASDAQ:BSEM

TradingView report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 14h ago

At $2 a share, BioStem Technologies (BSEM)'s COO exercises options to acquire 250,000 shares.

Stock Titan report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 17h ago

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

GlobeNewswire report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 20h ago

Third-quarter results are due Nov. 12; BioStem's management will discuss them at 4:30 p.m. ET.

Stock Titan report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

BioStem Technologies, Inc. SEC Filing (Oct 13, 2026) | BSEM EFFECT

Stock Titan report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

At $2 a share, BioStem Technologies (BSEM) CEO exercised options for 250,000 shares.

Stock Titan report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

BioStem Technologies, Inc. (BSEM) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

BioStem Technologies, Inc. Stock Price Today | BSEM Live Chart & News

Traders Union report covering BioStem Technologies Inc. (BSEM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BSEM Bull vs. Bear Conversation Board — What's Your Call at $1.12?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BSEM 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.14 (-11.6%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BSEM (D- • RQD 35/100) a Buy at $1.29?

Welcome to the BSEM (BioStem Technologies Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.02 (-20.9%)

Spot @ $1.29

Pump the brakes on BSEM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BSEM, but look at what you are paying: current EV/EBITDA multiples with 93.6% gross margins. Unless BioStem Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.60 (+24.0%)

Spot @ $1.29

BSEM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BSEM, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.29 (52-wk range $1.11 - $8.40), any beat on forward guidance forces shorts and underweight funds to chase.